Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

326
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
326
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

568
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
568
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

427
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
427
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thromboinflammation and hemostatic activation drive early mortality risk in pulmonary embolism.

Research and practice in thrombosis and haemostasis·2026
Same author

Enoxaparin, Tinzaparin, and Apixaban Modulate Cancer Cell Procoagulant Activity and Viability: Comparison with Quercetin.

Cancers·2026
Same author

A Comparative Study of Porcine and Ovine Derived Defibrotide: Coagulation Profiles, Molecular Characteristics, and DNA Content.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2026
Same author

Circulating Exosomal MicroRNAs as Potential Biomarkers for Pulmonary Embolism.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2026
Same author

Multifactorial thrombotic risk in Evans syndrome: a case report and review of the literature.

Thrombosis journal·2026
Same author

Venous thromboembolism in patients with multiple myeloma treated with B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy: A systematic review.

British journal of haematology·2026
Same journal

Monographic Issue on New Concepts in Acute Exacerbations of COPD.

Seminars in respiratory and critical care medicine·2026
Same journal

Bidirectional Clinical Interactions among Exacerbations and Comorbidities in COPD: A Narrative Review.

Seminars in respiratory and critical care medicine·2026
Same journal

Radiological Approach to Severe Respiratory Infections and Pulmonary Complications in Immunocompromised Patients.

Seminars in respiratory and critical care medicine·2026
Same journal

Two Sides of the Same Smoke: Decoding Respiratory Bronchiolitis-Associated Interstitial Lung Disease and Alveolar Macrophage Pneumonia.

Seminars in respiratory and critical care medicine·2026
Same journal

Role of Vaccination in the Prevention of ECOPD.

Seminars in respiratory and critical care medicine·2026
Same journal

Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Pharmacological Treatment of AECOPD New Perspectives.

Seminars in respiratory and critical care medicine·2026
See all related articles

Related Experiment Video

Updated: Mar 4, 2026

Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood
07:08

Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood

Published on: September 5, 2017

9.0K

The future of anticoagulation.

Debra A Hoppensteadt1, Walter Jeske, Jeanine Walenga

  • 1Department of Pathology, Loyola University Chicago, Maywood, IL 60153, USA. dhoppen@lumc.edu

Seminars in Respiratory and Critical Care Medicine
|February 28, 2008
PubMed
Summary
This summary is machine-generated.

Conventional treatments for thrombotic disorders like heparin and warfarin remain effective. Newer drugs offer advancements but are unlikely to fully replace established therapies, though combined approaches show promise.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.2K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.6K

Related Experiment Videos

Last Updated: Mar 4, 2026

Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood
07:08

Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood

Published on: September 5, 2017

9.0K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.2K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.6K

Area of Science:

  • Pharmacology
  • Hematology
  • Drug Development

Background:

  • Conventional management of thrombotic disorders relies on heparin, oral anticoagulants (e.g., warfarin), and aspirin.
  • Advancements include low molecular weight heparins and synthetic pentasaccharides, refining heparin's use.
  • Aspirin remains a primary drug for thrombotic and cardiovascular conditions.

Purpose of the Study:

  • To review current and emerging therapies for thrombotic disorders.
  • To assess the role of newer antiplatelet and anticoagulant agents in relation to conventional treatments.
  • To explore the potential of novel orally bioavailable anticoagulants.

Main Methods:

  • Review of existing literature on thrombotic disorder management.
  • Analysis of the development and clinical testing of new anticoagulant and antiplatelet drugs.
  • Comparison of the efficacy and limitations of conventional versus novel therapeutic agents.

Main Results:

  • Newer antiplatelet drugs (e.g., ADP receptor inhibitors, GPIIb/IIIa inhibitors) have shown limited effects, often tested in aspirin-treated patients.
  • Oral anticoagulants like warfarin offer convenient long-term management.
  • Development of orally bioavailable factor Xa and antithrombin inhibitors is ongoing, but bioavailability and therapeutic index remain challenges.

Conclusions:

  • Optimized use of conventional drugs is still the preferred approach for managing thrombotic disorders.
  • Newer drugs, while promising, are unlikely to completely replace conventional therapies in polytherapeutic strategies.
  • Combined modalities of newer drugs may eventually mimic the broad spectrum of heparins and warfarin, but require clinical validation for specific indications.